Fatty deposits in the eye called Drusen are metabolic wastes that build up and can distort the vision, damage the macula, and lead to blindness… 

The recommended dosage range is 1 capsule up to 3 times daily between meals, as guided and according to tolerance.

Each phthalate-free enteric vegicap of Lipid Zyme supplies:

Alkaloid:

 Black Pepper: Piperine (Piper nigrum) 3 mg

“Piper nigrum, significantly enhances the bioavailability of various nutrients through increased absorption. Piperine does this by inhibiting enzymes that metabolize drugs and nutritional substances, stimulating amino acid transporters in the intestinal lining, inhibiting P‑glycoprotein, and decreasing intestinal production of glucuronic acid.” Source: Piperine, Black Pepper (Piper nigrum)

Lipid Mobilizing Carotenoid:

 Kelp: Fucoxanthin 85% (Laminaria spp.) 3.1 mg

Fucoxanthin, a marine carotenoid, has been studied for its antioxidant and anti-inflammatory properties in retinal pigment epithelial (RPE) cells, particularly in contexts involving lipid peroxidation and impaired phagocytosis—processes linked to drusen formation (extracellular lipid-rich deposits) in age-related macular degeneration (AMD). Below are the most relevant quotes from peer-reviewed literature, selected for their direct ties to lipid handling, phagocytosis in lipid-rich environments, and drusen inhibition via reduced amyloid-beta (Aβ) deposition (a component exacerbating drusen).

“These results reveal that hydrogen peroxide activated the expression of drusen‑related proteins in ARPE‑19 cells. However, the increased expressions of Aβ1‑42 and BACE1 were consequently down‑regulated with fucoxanthin pretreatment… Since Aβ‑containing elements are associated with drusen and are considered to be the initial characteristic in retinal tissues with AMD pathogenesis, decreased expression of Aβ suggests it is related to the inhibition of drusen formation.” 

“Altogether, pretreatment with fucoxanthin may protect against premature senescence and cellular dysfunction in retinal cells by oxidative stress in experimental AMD animal and human RPE cell models.” Source: Cytoprotective Potential of Fucoxanthin in Oxidative Stress-Induced Age-Related Macular Degeneration and Retinal Pigment Epithelial Cell Senescence In Vivo and In Vitro

"Marked oxidative stress, inflammation, and phagocytosis disruption were evident in differentiated RPE cells following their exposure to visible light under a docosahexaenoic acid (DHA)-rich environment. Following pretreatment with fucoxanthin, however, the activated nuclear factor erythroid-derived-2-like 2 (Nrf2) signaling pathway was observed and, furthermore, when the fucoxanthin-pretreated RPE cells were irradiated with visible light, intracellular reactive oxygen species (ROS), malondialdehyde (MDA) levels and inflammation were obviously suppressed, while phagocytosis was significantly improved."

(This highlights fucoxanthin's enhancement of phagocytosis in lipid-rich (DHA, a polyunsaturated fatty acid) conditions, aiding clearance of lipid-laden debris akin to drusen precursors.)

Article Title: Fucoxanthin Pretreatment Ameliorates Visible Light-Induced Phagocytosis Disruption of RPE Cells under a Lipid-Rich Environment via the Nrf2 Pathway

Publication: Marine Drugs

Link: https://www.mdpi.com/1660-3397/20/1/15

"Due to their abundance of PUFAs [polyunsaturated fatty acids], lipid peroxidation of POSs [photoreceptor outer segments] occurs before being swallowed in the presence of light exposure. Given the close contact between RPE and POSs, this lipid peroxidation appears to be an important cause of visible light-induced damage to RPE cells. The results of this present study further confirmed that under the condition of visible light plus DHA exposure, obvious oxidative injury occurred in the RPE cells... [Fucoxanthin] can effectively inhibit oxidative stress and inflammation induced by visible light plus DHA in RPE cells."

(Emphasizes fucoxanthin's mitigation of lipid peroxidation in PUFA-rich settings, promoting lipid handling and reducing damage that contributes to drusen accumulation.)

Article Title: Fucoxanthin Pretreatment Ameliorates Visible Light-Induced Phagocytosis Disruption of RPE Cells under a Lipid-Rich Environment via the Nrf2 Pathway

Publication: Marine Drugs

Link: https://www.mdpi.com/1660-3397/20/1/15

"Our results show that the expression of Aβ and BACE1 decreased upon exposure to hydrogen peroxide... decreased expression of Aβ suggests it is related to the inhibition of drusen formation."
(Directly links fucoxanthin's reduction of Aβ (a drusen component) to potential inhibition of drusen, a key lipid deposit in early AMD.)
Article Title: Cytoprotective Potential of Fucoxanthin in Oxidative Stress-Induced Age-Related Macular Degeneration and Retinal Pigment Epithelial Cell Senescence In Vivo and In Vitro
Publication: Antioxidants (Basel)
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7923087/

"An administration of fucoxanthin significantly inhibited ROS generation, reduced MDA concentrations and increased the mitochondrial metabolic rate in oxidative stress-induced RPE cell damage."
(MDA measures lipid peroxidation; this quote underscores fucoxanthin's role in breaking down oxidized lipids, relevant to mobilizing drusen-like deposits.)
Article Title: Cytoprotective Potential of Fucoxanthin in Oxidative Stress-Induced Age-Related Macular Degeneration and Retinal Pigment Epithelial Cell Senescence In Vivo and In Vitro
Publication: Antioxidants (Basel)
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC7923087/

"Pretreatment of fucoxanthin significantly suppresses oxidative stress by reducing ROS and malondialdehyde concentration... Compared with control group, pretreated groups have shown less Aβ deposition, low expression of beta-site APP-cleaving enzyme 1 and the prevention of tight junction disruption."
(Reinforces reduced Aβ deposition and lipid peroxidation, tying to drusen mitigation in AMD pathogenesis.)
Article Title: Role of amyloid β-peptide in the pathogenesis of age-related macular degeneration
Publication: BMJ Open Ophthalmology
Link: https://bmjophth.bmj.com/content/6/1/e000774

Enzymes:

Quote: "Using systemic enzyme therapy or treatment with enzymes that affect the entire system also helps to inhibit the macular degeneration, augment blood circulation to the eye by means of disintegrating the cholesterol and fibrin accumulations, thereby enhancing the visual acuity or sharpness of vision."
(Emphasizes systemic oral enzymes' fibrinolytic and lipolytic actions to break down deposits like cholesterol/fibrin in drusen, improving ocular perfusion in AMD.)
Article Title: Enzyme Therapy
Publication: Herbs2000 (Clinical Herbal Guide)
Link: https://www.herbs2000.com/h_menu/t_enzyme.htm

 Lipase (120,000 FIP) 165 mg 

Lipase taken between meals in an enteric format acts as a systemic enzyme therapy to support mobilization of the fat component of Drusen deposits.

“Drusen are cold spots for proteolysis: while metalloproteinase activity is widespread throughout the RPE–choroid, drusen are cold spots for proteolysis, leading to speculation that high TIMP‑3 concentrations within drusen could inhibit MMPs and slow the proteolytic degradation of these deposits.” Source: Drusen are Cold Spots for Proteolysis: Expression of Matrix Metalloproteinases and Their Tissue Inhibitor Proteins in Age-related Macular Degeneration

 SBO (Soil-Based Organism): Neutral Protease (Bacillus licheniformis) (200,000 FIP) 125 mg 

Protease taken between meals in an enteric format acts as a systemic enzyme therapy to support mobilization of the protein component of Drusen deposits.

"Enteric-coated proteolytic enzyme preparations like Wobenzym and Phlogenzym are widely used for the so-called 'systemic enzyme therapy' both in humans and animals. Numerous publications reveal that oral proteolytic enzymes are able to stimulate directly the activity of immune competent cells as well as to increase efficiency of some of their products."
(Describes systemic immunostimulatory effects of enteric proteolytics, potentially aiding drusen clearance via enhanced phagocytosis and reduced inflammation in AMD.)
Article Title: Where do the immunostimulatory effects of oral proteolytic enzymes ('systemic enzyme therapy') come from? Microbial proteolysis as a possible starting point
Publication: Medical Hypotheses
Link: https://pubmed.ncbi.nlm.nih.gov/16870353/

 Bromelain 200,000 u/g (Ananas comosus) 150 mg

“The combination of bromelain and serrapeptase has been shown to be particularly effective in the treatment of inflammation and edema, and the use of these enzymes in synergy is known to amplify the benefits compared to the use of a single enzyme.” Source: Soft Tissue Inflammation and Edema: Mechanisms and Enzyme Integration

 Serrapeptase 400,000 u/g (Serratia marcescens) 17 mg

Serrapeptase degrades non‑living protein and fibrin. This ability has potential for modulating protein‑rich inflammatory deposits such as drusen, which are otherwise proteolytically ‘cold’ sites. "Serratiopeptidase is one of the most dominant anti-inflammatory drugs, with numerous therapeutic applications. The enzyme has anti-inflammatory, anti-biofilm, mucolytic, fibrinolytic, and wound-healing properties." Source: Serratiopeptidase: An integrated View of Multifaceted Therapeutic Enzyme

 Nattokinase 20,000 FU/g (Bacillus subtilis) 33 mg

"Nattokinase attenuates retinal neovascularization via modulation of Nrf2/HO‑1, glial activation and neuroinflammation." Source: Nattokinase Attenuates Retinal Neovascularization Via Modulation of Nrf2/HO-1 and Glial Activation